Coherus Oncology, Inc. (CHRS)
1.07
0.00 (0.00%)
USD |
NASDAQ |
Oct 09, 16:00
1.075
0.00 (0.00%)
After-Hours: 20:00
Coherus Oncology Free Cash Flow (Quarterly) : -62.09M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -62.09M |
| March 31, 2026 | -57.89M |
| December 31, 2025 | -19.72M |
| September 30, 2025 | -46.34M |
| June 30, 2025 | -46.63M |
| March 31, 2025 | -25.83M |
| December 31, 2024 | 28.61M |
| September 30, 2024 | -62.02M |
| June 30, 2024 | 59.73M |
| March 31, 2024 | -46.77M |
| December 31, 2023 | -12.97M |
| September 30, 2023 | -54.30M |
| June 30, 2023 | -39.02M |
| March 31, 2023 | -68.88M |
| December 31, 2022 | -100.04M |
| September 30, 2022 | -37.55M |
| June 30, 2022 | -50.92M |
| March 31, 2022 | -54.66M |
| December 31, 2021 | -52.79M |
| September 30, 2021 | 13.45M |
| June 30, 2021 | -0.603M |
| March 31, 2021 | 1.222M |
| December 31, 2020 | 32.17M |
| September 30, 2020 | 45.24M |
| June 30, 2020 | 57.81M |
| Date | Value |
|---|---|
| March 31, 2020 | 11.69M |
| December 31, 2019 | 17.32M |
| September 30, 2019 | 54.03M |
| June 30, 2019 | 12.50M |
| March 31, 2019 | -57.32M |
| December 31, 2018 | -47.58M |
| September 30, 2018 | -43.28M |
| June 30, 2018 | -35.54M |
| March 31, 2018 | -33.66M |
| December 31, 2017 | -30.03M |
| September 30, 2017 | -43.32M |
| June 30, 2017 | -56.54M |
| March 31, 2017 | -74.97M |
| December 31, 2016 | -90.46M |
| September 30, 2016 | -62.45M |
| June 30, 2016 | -27.69M |
| March 31, 2016 | -78.46M |
| December 31, 2015 | 4.123M |
| September 30, 2015 | -62.05M |
| June 30, 2015 | -21.85M |
| March 31, 2015 | -34.38M |
| December 31, 2014 | -33.77M |
| September 30, 2014 | -5.977M |
| June 30, 2014 | -1.51M |
| March 31, 2014 | 14.48M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Enanta Pharmaceuticals, Inc. | -9.979M |
| ACADIA Pharmaceuticals, Inc. | 95.69M |
| Alnylam Pharmaceuticals, Inc. | 292.04M |
| Anika Therapeutics, Inc. | -2.133M |
| Savara, Inc. | -29.97M |